1. Home
  2. PMO vs ADAG Comparison

PMO vs ADAG Comparison

Compare PMO & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Putnam Municipal Opportunities Trust

PMO

Putnam Municipal Opportunities Trust

N/A

Current Price

$9.05

Market Cap

264.4M

Sector

Finance

ML Signal

N/A

Logo Adagene Inc.

ADAG

Adagene Inc.

N/A

Current Price

$3.19

Market Cap

222.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PMO
ADAG
Founded
1993
2011
Country
United States
China
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
264.4M
222.2M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
PMO
ADAG
Price
$9.05
$3.19
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $8.25
AVG Volume (30 Days)
92.1K
★ 222.2K
Earning Date
01-01-0001
04-01-2026
Dividend Yield
★ 4.10%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$25.02
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.02
$1.44
52 Week High
$10.87
$4.85

Technical Indicators

Market Signals
Indicator
PMO
ADAG
Relative Strength Index (RSI) 18.93 36.31
Support Level N/A $2.78
Resistance Level $10.80 $3.19
Average True Range (ATR) 0.15 0.30
MACD -0.05 -0.03
Stochastic Oscillator 2.00 18.18

Price Performance

Historical Comparison
PMO
ADAG

About PMO Putnam Municipal Opportunities Trust

Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, leases, local, Housing, education, and Others.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: